Prescription drug · ANDA
BUTALBITAL and ACETAMINOPHEN NDC 70752-148
Butalbital 50 mg/1; Acetaminophen 325 mg/1 · Tablet · Oral · QUAGEN PHARMACEUTICALS LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70752-148-10 | 70752014810 | 100 TABLET in 1 BOTTLE (70752-148-10)Marketed from May 1, 2024 | |
| 70752-148-14 | 70752014814 | 500 TABLET in 1 BOTTLE (70752-148-14)Marketed from May 1, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- BUTALBITAL and ACETAMINOPHEN
- Generic name (nonproprietary)
- butalbital and acetaminophen
- Active ingredients
- Butalbital — 50 mg/1Acetaminophen — 325 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- QUAGEN PHARMACEUTICALS LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 214291
- Marketing start
- Listing expires
- DEA schedule
- CIII
- Other FDA classes
- Barbiturates (Chemical structure)
- Identifiers
- Product ID 70752-148_d113b27d-2b74-45ad-b095-d0cded8d4f6bSPL ID d113b27d-2b74-45ad-b095-d0cded8d4f6bSPL set ID 2eb09253-7f59-401e-afbc-70bb9600fedfRxCUI 197426UNII KHS0AZ4JVK, 362O9ITL9D
- Pharmacologic class
- Barbiturate
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N470752014810followed by a unit qualifier and the quantityPackage 70752-0148-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Butalbital and acetaminophen tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.
Excerpt only. Read the full label for complete information.